ArticleIntensive care medicine experimental2020
Use of the CytoSorb adsorption device in MDMA intoxication: a first-in-man application and in vitro study.
Article in Intensive care medicine experimental, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Drug Clearance and Dosing During CytoSorb Hemoadsorption: A Systematic Review.Critical care explorations · 2026Pooled it
- Evaluation of Hemoadsorption Capacity of the CytoSorb Adsorber for Toxic Doses of Diclofenac and Meloxicam in Porcine Plasma.Journal of clinical apheresis · 2026Article
- Antibiotics and Other Drugs Removal by the CytoSorbAntibiotics (Basel, Switzerland) · 2026Review
- Haemoadsorption to remove inflammatory mediators in sepsis: past, present, and future.Intensive care medicine experimental · 2025Review
- The use of CytoSorb hemoadsorption in critically ill patients: a narrative review.Frontiers in medicine · 2025Review
- Pilot study: In vitro reduction of hemoglobin from canine blood with hemoperfusion using the Cytosorb® adsorber.PloS one · 2025Article
- Hemoadsorption therapy for myoglobin removal in rhabdomyolysis: consensus of the hemoadsorption in rhabdomyolysis task force.BMC nephrology · 2024Article
- Successful use of extracorporeal life support and hemadsorption in the context of venlafaxine intoxication requiring cardiopulmonary resuscitation: a case report.Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2024Article
- Hepatic injury and hepatic failure adverse events in 3,4-methylenedioxymethamphetamine users reported to the FDA Adverse Event Reporting System.Frontiers in psychiatry · 2024Article
- [Hemoperfusion in anesthesia and intensive care medicine: benefits, risks, and evidence for different systems].Die Anaesthesiologie · 2023Review
- CytoSorb hemoperfusion markedly attenuates circulating cytokine concentrations during systemic inflammation in humans in vivo.Critical care (London, England) · 2023Article
- Therapeutic Modulation of the Host Defense by Hemoadsorption with CytoSorbInternational journal of molecular sciences · 2021Article
- Pharmacokinetics of anti-infective agents during CytoSorb hemoadsorption.Scientific reports · 2021Article
- Hemoadsorption eliminates remdesivir from the circulation: Implications for the treatment of COVID-19.Pharmacology research & perspectives · 2021Article
- CytoSorb removes MDMA in vitro, but is it an effective therapy in vivo?Intensive care medicine experimental · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") abuse is frequent, and overdosing might cause severe and eventually lethal multi-organ failure. To date, there is no causal therapy of MDMA intoxication and removal of MDMA from the circulation might be a reasonable measure to prevent adverse courses after overdosing. We present here first-in-man experience and in vitro data supporting a potential role of an adsorber device in severe MDMA overdosing.
resultsWe applied a CytoSorb adsorber device in a 21-year-old male presenting with severe MDMA intoxication and multi-organ failure, including neurological impairment, hyperpyrexia, rhabdomyolysis, oliguric renal failure, liver failure, and coagulopathy with disseminated gastrointestinal and intramuscular bleeding. Use of the adsorber device was associated with a decline in MDMA concentrations in serum from 540 to 140 ng/ml within the first 24 h, a decrease of interleukin 6 and myoglobin levels, and subsequent clinical improvement. The patient was discharged from hospital after restoration of organ function and full neurological recovery. Effective elimination of MDMA by the adsorber device could be confirmed in vitro, when the device lowered MDMA concentrations to non-detectable levels.
conclusionsWe report here first-in-man experience and in vitro data showing the capacity of a CytoSorb adsorber device for MDMA removal. Early integration of CytoSorb use may enhance the management of severe MDMA intoxication, though we cannot prove whether clinical improvement was directly related to elimination of MDMA or beneficial effects on rhabdomyolysis, hyperinflammation, or liver failure. Our findings encourage further investigation of the CytoSorb adsorber device in a prospective study and to evaluate its use for other intoxications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.